Clinical Trial Update: A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 [Phase 3]

View source ↗

Summary

The Phase 3 open-label extension MP-101-CL-001 for short bowel syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• MP-101

Snippet

Sponsor: Marathon Pharmaceuticals, LLC | Conditions: Short Bowel Syndrome, Short Gut Syndrome | Phase 3 | Status: WITHDRAWN